magent
Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.
Listing completeness · 80/100
Presence of published information only. Not a security, reliability or performance score. Same rules for Datoka and external listings.
- Name and traceable source
- 10/10 · Present
- Meaningful description
- 10/10 · Present
- Connection or installation reference
- 20/20 · Present
- Dedicated documentation or source repository
- 0/15 · Missing or insufficient
- Explicit free access or numeric tariff
- 20/20 · Present
- Declared integration protocol
- 10/10 · Present
- Source updated within 90 days
- 10/10 · Present
- Declared capability names
- 0/5 · Missing or insufficient
Evaluated 2026-10-07 · Method listing-completeness-1. Scoring rules
Connect & use
Connect through the publisher’s supported interface. Any credentials or payments are handled by the provider.
x402 resource
https://api.magentlab.com/api/calc/prevailRead the current payment requirements with a compatible client before authorizing a call.
Categories and declared capabilities
Topic categories are derived from publisher text for discovery, not independently verified capabilities.
The registry does not provide a verified tools list. See the observations, when available, for any tools/list check; a published tools list does not establish that execution succeeds.
Evidence, with its limits.
This listing is indexed. Any domain claim or endpoint observation appears separately with its date and limited scope. No payment execution, factual accuracy or safety certification is inferred.